Blood test strategy may spare kidney patients from unnecessary biopsies
NCT ID NCT04774575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether using non-invasive blood biomarkers to guide when to perform a biopsy is as safe as doing routine biopsies at set times in kidney transplant recipients. 342 patients were randomly assigned to either a biomarker-guided group or a routine biopsy group. The goal was to see if the biomarker approach could reduce the number of biopsies without missing signs of organ rejection.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- biomarker-guided strategy (non-invasive blood tests)
- What this could lead to
- If successful, this approach could reduce the need for painful and risky routine biopsies in kidney transplant patients, making follow-up safer and more comfortable.
- What could go wrong
- This is a completed trial, but the strategy may not detect all cases of rejection, and results may not apply to all transplant centers or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
342 people
The number who actually took part.
- Started
-
Dec 2021
- Finished
-
May 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. All men and women, age ≥18 years old. 2. Subject must be a recipient of a single renal transplant from a deceased or living donor. 3. Subject is willing and able to provide signed written informed consent and willing to comply with study procedures 4. Women of Childbearing Potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL\]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of clinical trial Exclusion Criteria: 1. Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive blood PCR result at the moment of transplant). 2. Subjects with known human immunodeficiency virus (HIV) infection. 3. Patients with active systemic infection that requires the continued use of antibiotics. 4. Patients with neoplasia except localized skin cancer receiving appropriate treatment. 5. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment. 6. Subjects who are legally detained in an official institution. 7. Primary non-function or early graft loss due to mechanical/surgical complications. 8. Death within the first 6 months after transplantation. 9. Any condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient 10. History of multi-organ transplant (interference with rejection natural history).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bellvitge University Hospital
Barcelona, 08907, Spain
-
Charité-Universitätsmedizin,
Berlin, 10117, Germany
-
Charité-Universitätsmedizin, Berlin
Berlin, 10117, Germany
-
Geneva University Hospitals
Geneva, Canton of Geneva, 1205, Switzerland
-
Nantes Hospital
Nantes, 44000, France
-
Necker Hospital, Paris
Paris, Île-de-France Region, 75015, France
-
Saint-Louis Hospital, Paris
Paris, Île-de-France Region, 75010, France
-
Vall d'Hebron Hospital
Barcelona, 08035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can kidney transplants succeed without steroids?
- Which nerve block offers better pain relief for kidney donors?
- Can a new drug combo help kidney transplants last longer?
- Gene test could predict kidney cancer in transplant patients
- Pilates promises new hope for kidney transplant recovery
- Anesthesia choice may boost kidney transplant success